Equity
€610,913 from €2.0m in 2023
Equity fell by 69% in 2 years.
ANEUROTECH
Lifetime
4 annual accounts with figures on one time axispeak -€1,803 (2022)
-€31,077▲ €1,756
lowest -€701,586 (2025)
-€701,586▼ €46,307
peak €2.0m (2023)
€610,913▼ 53.5%
€2.3m▲ 9.9%
Board4 names since 2022
1 director
Documentsfilings and deeds
31-08-202631 days late
2025abbreviated format
Loss of €701,586Equity from €1.3m to €610,913Cash from €13,388 to €1,836
Key points
from the 2025 annual accountsLosses
-€1.7m in four years
Every financial year from 2022 to 2025 closed with a loss. 2025 was the heaviest.
Debts
€2.3m 79% of the balance sheet
Financial debts 78%Suppliers 7%Taxes and wages 1%Other 15%
Of this, €499,459 falls due within a year.
Investments
€107,824 0.2 × depreciation
Green is investment, beige is depreciation.
Filings
4 annual accounts 4 late
The 2022 accounts came latest: 92 days after the end of the period.
Position in the sector
-€701,586
Lower net result than 82% of companies in research and development. Sector median €423 · 341 companies.
Turnover not published (abbreviated or micro format)
Checked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 690 companies had the same profile as ANEUROTECH has now. Each dot stands for 2 companies, two years later.
89.1%
were still trading
4.3%
stopped another way
5.2%
went bankrupt
Another 1.3% stopped without a precise date, possibly only after those two years.
Test of the method
The method was tested on the 497,762 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 690 companies, not a prediction for ANEUROTECH. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Board and ownership
Managing director,
Director, since 09-11-2022
- 114 sharesdeed of 08-03-2024
- 38 sharesdeed of 08-03-2024
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0785263993
Merger: ANeuroTech takes over ANeuroTech IP
88 new shares · 152 new shares · Contributions: (€300,390, 114 shares); (€100,130, 38 shares) · General meeting of 05-12-2023 · Gazette deed
Merger proposal: ANeuroTech takes over ANeuroTech IP
Gazette deed
Capital increase of €150,195
57 new shares · Contribution: · General meeting of 14-07-2023 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| ANEUROTECH Alken | €2.9m | -€31,077 | 21.0% | - |
| THERAtRAME Liège | €2.7m | -€869,288 | 65.8% | 10.1 |
| SYNLOCK Jemeppe-sur-Sambre | €2.7m | -€43,918 | 30.3% | 0 |
| DAU Technology Antwerp | €3.3m | -€10,602 | -17.4% | - |
| LIVEDROP Liège | €4.3m | -€5,798 | 55.7% | 6.8 |
| CANCER STATE THERAPEUTICS Charleroi | €4.0m | -€105,252 | 94.4% | - |
| OLFADOG BIOTECH Waterloo | €1.8m | -€8,187 | 80.0% | - |
These companies have the same main activity as ANEUROTECH: research and development on biotechnology (NACE 72101). They are comparable in size and age: total assets between €1.8m and €4.3m, founded between 2021 and 2022.
Official details
Source: KBO- Status
- Active since 14-04-2022Normal situation
- Activity
- Research and development on biotechnologyNACE 72101and 3 others
- Establishment unit
- 2.330.918.0173570 Alken, since 21-04-2022
- Financial year end
- 31 December
- Peppol
- Reachable since 04-12-2025
Insights on ANEUROTECH
ANEUROTECH files the abbreviated format. That format states no turnover. The gross margin fell from -€1,803 in 2022 to -€31,077 in 2025.
Since April 2022, has been managing director.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about ANEUROTECH
- What is the company number of ANEUROTECH?
- The company number of ANEUROTECH is 0785.263.993. The VAT number is the same number with BE in front: BE 0785.263.993.
- Where is ANEUROTECH based?
- The registered office is at Alkerstraat 30 A, 3570 Alken.Company details
- What does ANEUROTECH do?
- According to the KBO register, the main activity is research and development on biotechnology (NACE 72101).
- What is the legal form of ANEUROTECH?
- ANEUROTECH is a private limited company (BV).
- When was ANEUROTECH founded?
- ANEUROTECH was founded on 14-04-2022.
- Is ANEUROTECH still active?
- Yes, ANEUROTECH is an active enterprise in the KBO register.
- What is the turnover of ANEUROTECH?
- The annual accounts for financial year 2025 state no turnover. The abbreviated or micro format does not require it.Financials
- Is ANEUROTECH profitable?
- In financial year 2025, ANEUROTECH made a loss of €701,586.
- Where can I find the annual accounts of ANEUROTECH?
- ANEUROTECH filed 4 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of ANEUROTECH due?
- ANEUROTECH must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.